Octapharma AG

5 trials 4 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

4 Recruiting

1 Completed trials

13 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase IV

Phase III: 3 Phase IV: 2

Oversight events:

10 temporary halts across 2 trials

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acquired antithrombin III deficiency 1 Heparin resistance 1

Top IMPs

ANTITHROMBIN III HUMAN 2 SIMOCTOCOG ALFA 2 HUMAN COAGULATION FACTOR IX, PROTEIN C, HUMAN COAGULATION FACTOR VII, PROTEIN S, HUMAN COAGULATION FACTOR II, HUMAN COAGULATION FACTOR X 1 HUMAN PLASMA DERIVED ANTITHROMBIN 1 SODIUM CHLORIDE 1

All trials

5 total

Nuwiq Dosing and outcomes In the ManagEment of women/girls with haemophilia A Needing FVIII treatment for Surgery – an International, Open-l… Recruiting

2022-502061-17-00 Phase IV 6 countries SIMOCTOCOG ALFA
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting

2024-515830-34-00 Phase III 8 countries ANTITHROMBIN III HUMAN; HUMAN PLASMA DERIVED ANTITHROMBIN
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo … Recruiting

2023-507560-39-00 Phase III 8 countries ANTITHROMBIN III HUMAN; SODIUM CHLORIDE
Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER) Recruiting

2022-502060-21-00 Phase IV 6 countries SIMOCTOCOG ALFA
Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th… Ended

2024-515485-14-00 Phase III 6 countries HUMAN COAGULATION FACTOR IX, PROTEIN C, HUMAN COAGULATION FACTOR VII, PROTEIN S,…

Showing 1–5 of 5 trials

← All sponsors A–Z